The partnership to tokenize innovative drug assets boosted Chuangsheng’s shares nearly 10%, with Huajian Medical’s market cap climbing HK$14 billion in two months.
Huajian Medical and Chuangsheng Group unveiled a $1.5 billion collaboration on September 22 to tokenize innovative drug assets via a Real World Asset (RWA) model. The news sparked a near 10% rally in Chuangsheng’s share price and lifted Huajian Medical’s market capitalization by HK$14 billion over two months. While regulators issued guidance to cool the overheated market, investor interest in the initiative remains high.